Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout

What Happened

Vertex will pay $85 a share. That is roughly double Crinetics’ closing price the day before Vertex announced the deal.

Crinetics makes Palsonify, a pill for acromegaly, a rare disorder that causes excess growth hormone. Patients previously relied on regular injections, so a once-daily pill is a real upgrade in convenience.

“Investors will debate this (stock was down 1.8% after hours), but we view this as reasonable if the peak sales number can be achieved.”

Once a company announces a cash buyout, its stock stops trading on its own business prospects. It trades toward the agreed price instead.

Market Context

William Blair analyst Myles Minter said the price tag makes sense if that sales target holds up.

Crinetics is already close to that $85 target. The Riot Platforms Bitfarms takeover played out the same way, with shares settling near the offer price.

Why It Matters

Vertex, known for its cystic fibrosis drugs, is betting big on that convenience. It has a second drug in late-stage trials for another rare hormone condition. Together, the two products could bring in more than $5 billion a year at their peak.

Most of the reward has already landed. What remains is a small gap, plus the risk that the deal falls through before it closes in the third quarter.

Details

Crinetics Pharmaceuticals shares nearly doubled on Monday, July 6 after Vertex Pharmaceuticals agreed to buy the company for $10 billion in cash.

What Vertex Is Actually Buying

Retail sentiment on Crinetics flipped from bearish to bullish within a day. The GameStop eBay takeover saga shows how fast retail mood can swing on buyout news.

Is There Any Upside Left?

The post Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout appeared first on BeInCrypto.